Only 35% of advanced cancer patients received comprehensive genomic profiling testing. Tested patients were more likely to receive targeted therapies. Testing rates increased slightly over time and ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

It’s common to wait until something feels “off” before making an appointment to see a healthcare provider. But waiting for noticeable symptoms can mean missing the chance to catch health issues early.

Almost all of us have been touched by cancer at some point in our lives. If we haven’t had it, chances are we know a loved one or a friend who has. When someone dies from cancer, families go through ...

Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations. Biomarker testing for patients with lung cancer is critical, ...

Precision Care Companion (PCC) enhances biomarker testing and precision therapy adoption in community oncology, uniting practices, labs, and biopharma for improved patient outcomes. PCC focuses on ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

We tried out one of the most advanced baseline diagnostic panels available – here’s what we discovered about our health with this biomarker testing… Preventative healthcare has long been the preserve ...

Biomarker testing is crucial for personalized oncology care, aiding in risk stratification and treatment decisions, but faces challenges in uptake and education. Multistakeholder partnerships and ...

Every year, America’s medical research pipeline produces new treatments, new technologies and new ways to improve patient care. Often, the real challenge is ensuring policy keeps pace with these ...

Gov. Tate Reeves has signed a bill requiring state-regulated health insurance plans in Mississippi to cover biomarker testing ...

Only a third of patients with advanced cancer had molecular testing to help guide the use of targeted therapies, a review of 26,000 patients showed. Overall, 35% of patients' records had evidence of ...